Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Zetina Toaché
Oncomédica. Multimédica
Guatemala
Biologia Molecular
Origen de Terapias Blanco
Que es Terapia Blanco?
“ It is much more important to know
what kind of patient has a disease, than to
know what kind of disease a patient has”
Caleb Parry. 18th Century physician, Bath.
DNA
Estructura del DNA
Watson y Crick. 1953
Cristalografía
Rx. Rosalind
Franklin. 1950
Dogma Central de Biologia
CICLO CELULAR
Enzimas fase S
Topoisomerasa
Telomerasa
Mitosis
Muerte Celular Programada
APOPTOSIS
Guardian del Genoma
ARF: ADP Ribosylation Factor
mdm2: mouse double minute
ubiquinitisacion 53 Kd
• Es llevada al proteosoma
para su destruccion en
pequeñas cadenas de
aminoacidos
Enfoque nuevos requeridos
G2 G1
G0
S
1
7. Multiple sites 7 2
e.g. agents perturbing 3. Tumour-associated
angiogensis and surface antigens/markers
receptors Tumour Gangliosides, CEA, MAGE,
6 cell 3 CD20, CD22
6. Extracellular matrix 4
5
4. Proteasome
5. Cell-survival pathways
Cyclin-dependent kinases,
mTOR, cGMP, COX-2, p53, Bcl-2
Bronchud MH, et al eds. Principles of Molecular Oncology 2nd ed.Humana Press, Totowa NJ, 2003
Nuevas Terapias Blanco en Oncologia
HER2-R IGF-1R
EGFR inhibitors inhibitors MUC-1
inhibitors Directed
Metastases antibodies
Inhibitors
mTOR Src
Anti- inhibitors inhibitor
Angiogenesis Farnesyl
HIF
Transferase
inhibitor MEK Cell Cycle Inhibitors
inhibitors inhibitors
Raf Aurora Kinase
HSP90
inhibitor inhibitor
inhibitors
Proteasome Pro-apoptotic
inhibitor drugs
Mdm2
inhibitor Kinesins
Tubulin-
Death interacting HDAC
Receptors agents Inhibitors
TRANSDUCCION DE SENALES
Membrana Celular
Citoplasma
TKI
P P
• Binds to the ATP
Phosphorylation pocket of the TKD
• Prevents
P
phosphorylation
AKT P MAPK
G2 S
Tumor cell
survival Tumor cell Apoptosis G1 arrest
proliferation
TKI = tyrosine kinase inhibitor.
Data from Moyer et al. Cancer Res. 1997;57:4838.
Proto oncogen si se
Amplifica Oncogen y
RECEPTOR DE FC